Full-Time

Senior Manager

Regulatory Planning

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$135k - $175kAnnually

Senior

San Carlos, CA, USA

Hybrid position.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • 5+ years of Regulatory Planning or equivalent experience.
  • Proficient in Smartsheet and OnePager.
  • Understanding of eCTD and relevant submission formatting, transmittal and archiving regulations and guidelines.
  • Knowledge of ex-US eCTD submissions and submissions processes.
  • Foster strong collaborative relationships with external partners and vendors to ensure both high quality of submissions and compliance with regulatory processes and standards.
  • Outstanding interpersonal and communication (written and verbal) skills: able to work with multiple groups of people at one time, remaining calm, professional, diplomatic and positive.
Responsibilities
  • Understand regulatory submissions and activities.
  • Ensure effective communication of regulatory submissions and activities globally, to help ensure timely and accurate dissemination of regulatory workstreams.
  • Identify, establish, and manage databases/information sources to track key deliverables and information.
  • Provide scenario and visualization support to drive proactive planning and rapid and informed decision making.
  • Develop, execute, and maintain submission delivery plans, submission content plans, and proactively provide status updates.
  • Identify regulatory bottlenecks or resource constraints based on Planning outputs.
  • Demonstrate strategic mindset to support comprehensive strategies that align with organizational goals and regulatory requirements for efficient execution.
  • Identifies opportunities for process improvements and create best practices.
  • Manages the input, upkeep, and revisions of project plans for assigned projects, highlighting any unforeseen changes in resource requirements.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to specifically inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses exclusively on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for research and development.
  • Increased demand for targeted cancer therapies aligns with their RAS-focused treatments.
  • AI and machine learning trends offer potential to optimize drug development processes.

What critics are saying

  • EQRx acquisition may pose integration challenges affecting operational efficiency.
  • $600M public stock offering could lead to shareholder dilution and affect stock price.
  • Focus on RAS-addicted cancers limits market scope and exposes to competitive risks.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • They focus on RAS-addicted cancers, a niche but significant oncology market.

Help us improve and share your feedback! Did you find this helpful?